Eli Lilly and - LLY Stock Forecast, Price & News

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company increased their target price on shares of Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. UBS Group upped their target price on Eli Lilly and to $335.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 27th. Mizuho boosted their price objective on Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. Finally, Morgan Stanley upped their price objective on Eli Lilly and from $369.00 to $395.00 and gave the company an "overweight" rating in a report on Friday, July 8th. Three equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $317.00.

Eli Lilly and Stock Up 1.9 %

Shares of LLY Stock traded up $6.05 on Friday, reaching $322.77. 3,365,751 shares of the company's stock traded hands, compared to its average volume of 2,901,203. The business's 50 day moving average price is $315.96 and its two-hundred day moving average price is $293.19. The company has a market capitalization of $306.69 billion, a P/E ratio of 50.51, a price-to-earnings-growth ratio of 2.16 and a beta of 0.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.85 and a current ratio of 1.10. Eli Lilly and has a 12-month low of $220.20 and a 12-month high of $335.33.

Eli Lilly and (NYSE:LLY - Get Rating) last released its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). The business had revenue of $6.49 billion for the quarter, compared to analysts' expectations of $6.85 billion. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The company's revenue was down 3.7% compared to the same quarter last year. During the same period last year, the firm earned $1.87 EPS. On average, equities analysts forecast that Eli Lilly and will post 7.96 earnings per share for the current year.

Eli Lilly and Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be paid a $0.98 dividend. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend is Friday, August 12th. Eli Lilly and's dividend payout ratio (DPR) is presently 62.52%.

Insider Buying and Selling

In other Eli Lilly and news, SVP Alonzo Weems sold 656 shares of the company's stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $304.50, for a total value of $199,752.00. Following the transaction, the senior vice president now directly owns 8,136 shares of the company's stock, valued at approximately $2,477,412. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Eli Lilly and news, SVP Alonzo Weems sold 656 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total value of $199,752.00. Following the completion of the sale, the senior vice president now directly owns 8,136 shares in the company, valued at $2,477,412. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $313.44, for a total transaction of $313,440.00. Following the transaction, the chief accounting officer now owns 6,274 shares in the company, valued at approximately $1,966,522.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,114,591 shares of company stock worth $355,690,328. Corporate insiders own 0.12% of the company's stock.